Here are seven new shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists.
Editor’s note: The drugs listed are in alphabetical order
- Atazanavir sulfate capsules: Bristol Myers Squibb has permanently discontinued its Reyataz 200 mg and 300 mg capsules, used as part of antiviral therapy for HIV.
- Atazanavir sulfate oral powder: Bristol Myers Squibb has permanently discontinued Reyataz 50 mg oral powder used in pediatric and adult patients for HIV treatment.
- Bosentan tablet: Actelion Pharmaceuticals has discontinued both 62.5 mg and 125 mg presentations of Tracleer, a treatment used for pulmonary arterial hypertension.
- Metoprolol tartrate tablet: Aurobindo Pharma USA has permanently discontinued all 25 mg, 50 mg and 100 mg strengths of its cardiovascular drug used to manage high blood pressure and chest pain.
- Octreotide intramuscular injection kits: Teva Pharmaceuticals has all 10 mg, 20 mg and 30 mg octreotide kits on back order; the drug is used to manage symptoms of certain hormone-secreting tumors. The company estimates resupply date in mid- to late June. Novartis’ Sandostatin LAR Depot remains available as an alternative.
- Scopolamine transdermal system: Baxter and Teva report shortages of scopolamine patches used to prevent nausea and vomiting. Baxter cannot estimate a resupply date, while Teva expects resupply of several presentations between July and October. Alternatives from Ingenus, Padagis, Rhodes, Viatris and Zydus remain available.
- Triamcinolone acetonide injectable suspension: Multiple manufacturers, including Teva, Eugia, Hikma, Long Grove and Viatris, report shortages of 40 mg/mL injectable formulations commonly used to treat inflammation and allergies. Amneal and Bristol Myers Squibb have several presentations available and resupply estimates vary from early June to late July, depending on the manufacturer.
